Vivere Oncotherapies Raises Over $10M to Develop Targeted Therapies for Solid Tumors, Led by YK Bioventures.
Amount Raised
$10 Million
Round Type
Funding Round
BerkeleyBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Vivere Oncotherapies has announced over $10M in funding to develop cancer therapies that activate the immune system for solid tumors. The funding is led by YK Bioventures, with additional support from Pillar, Berkeley Frontier Fund, Freeflow Ventures, and The National Cancer Institute. Vivere aims to create transformative treatments for difficult-to-treat cancers, improving options for patients. The company is focused on building a platform to tackle immunologically cold tumors that evade detection.
Quick answer
Vivere Oncotherapies raised $10 Million in a Funding Round round, dated January 13, 2026. Investors: Pillar, Berkeley Frontier Fund, Freeflow Ventures, The National Cancer Institute and YK Bioventures. Vivere Oncotherapies is based in Berkeley, California, United States.
- How much did Vivere Oncotherapies raise?
- Vivere Oncotherapies raised $10 Million in a Funding Round round on January 13, 2026.
- Who invested in Vivere Oncotherapies?
- Pillar, Berkeley Frontier Fund, Freeflow Ventures, The National Cancer Institute and YK Bioventures are named as investors in this round.
- What does Vivere Oncotherapies do?
- Vivere Oncotherapies develops cancer therapies that activate the immune system to detect and selectively destroy cancer cells in tumors that would otherwise remain hidden.
- Where is Vivere Oncotherapies based and how big is it?
- Vivere Oncotherapies is based in Berkeley, California, United States. Fundz records about 10 employees.
- Who are the decision-makers at Vivere Oncotherapies?
- Fundz holds 1 contact at Vivere Oncotherapies. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Vivere Oncotherapies that raised within 45 days of this round, from Fundz verified event records.
- Faeth Therapeutics raised $200M (Post-IPO Equity) on February 18, 2026.
- Aerska raised $39M (Series A) on February 9, 2026.
- Corxel raised $287M (Series D) on January 26, 2026.
- MAIA Biotechnology raised $1.5M on December 22, 2025.
- Tivic raised $16M on December 10, 2025.
- Tivic raised $12M on December 10, 2025.
Who to call at Vivere Oncotherapies, and when
A new round usually means Vivere Oncotherapies is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Vivere Oncotherapies raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Vivere Oncotherapies, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Vivere Oncotherapies. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vivere Oncotherapies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Vivere Oncotherapies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.